0
World
US FDA plans ultra-fast review of 3 psychedelic drugs after Trump directive
April 24, 2026
Scroll
Posted 5 hours ago by
The Food and Drug Administration said on Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest indication of the Trump administration’s commitment to the experimental treatment approach. President Donald Trump signed an executive order last weekend directing the FDA and other federal agencies to speed access and loosen restrictions on psychedelics, a class of hallucinogenic drugs which remain illegal...
South China Morning Post
Coverage and analysis from Hong Kong. All insights are generated by our AI narrative analysis engine.
Hong Kong
Bias: lean left
People's Voices (0)
Leave a comment
0/500
Note: Comments are moderated. Please keep it civil. Max 3 comments per day.